Glutathionarsenoxide
Alternative Names: GSAOLatest Information Update: 24 Oct 2021
At a glance
- Originator University of New South Wales
- Developer Institute of Drug Technology Australia; University of New South Wales
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; HIV infections
Most Recent Events
- 03 Apr 2003 No development reported - Preclinical for Cancer in Australia (unspecified route)
- 03 Apr 2003 No development reported - Preclinical for HIV infections treatment in Australia (unspecified route)
- 09 Nov 2000 Preclinical development for Cancer in Australia (Unknown route)